Allopurinol tablets are taken by mouth as a regular urate-lowering treatment for people with gout, recurrent uric acid stones, or high uric acid caused by cancer treatment. They reduce the body’s production of uric acid rather than treating pain during an active attack.
Allopurinol is a xanthine oxidase inhibitor. Xanthine oxidase is an enzyme involved in the final steps of uric acid production. By blocking this enzyme, Allopurinol lowers uric acid in the blood and urine.
Allopurinol tablets are taken orally on a regular schedule. Dosing differs between strengths and between users, so there is no single amount that suits everyone. Prescribers usually individualize treatment according to uric acid levels, kidney function, other medicines, and the reason for therapy.
Many people expect treatment to stop at the first normal uric acid result. That is a common mistake. Uric acid may fall before older crystal deposits have dissolved, so ongoing treatment is often needed to prevent renewed accumulation.
Allopurinol tablets contain allopurinol, a xanthine oxidase inhibitor. This active substance reduces the body's production of uric acid by blocking an enzyme involved in its final production steps. The tablets are taken by mouth as a regular urate-lowering treatment.
The body converts hypoxanthine into xanthine, then converts xanthine into uric acid. Allopurinol and its active metabolite, oxypurinol, interrupt this pathway by inhibiting xanthine oxidase. Less uric acid is produced, and more soluble precursor substances can be eliminated through the kidneys.
This gradual reduction matters. Lower serum urate allows existing deposits to dissolve over time, which can reduce flare frequency, shrink tophi, and limit crystal-related joint injury. The American College of Rheumatology identifies xanthine oxidase inhibitors as first-line urate-lowering therapy for gout management [1].
Allopurinol is used when uric acid reduction is needed over the long term. It is commonly prescribed for chronic gout, recurrent uric acid kidney stones, and hyperuricemia linked to rapid cancer-cell breakdown during certain treatments.
It is not an acute-flare rescue pill.
Gout pain occurs when the immune system reacts to monosodium urate crystals in or around a joint. The big toe is a familiar site, though the ankle, knee, wrist, elbow, and fingers can also be affected.
Allopurinol lowers the cause of crystal formation. It does not remove crystals overnight. During the early phase, changing urate levels can disturb existing deposits and briefly make a flare more likely. This does not automatically mean the treatment has failed.
Uric acid can crystallize in concentrated urine, especially when urine is persistently acidic or fluid intake is low. Reducing uric acid production can help prevent recurrent uric acid stones in appropriate patients.
Tumour lysis syndrome is different from ordinary gout. It can occur when large numbers of cancer cells break down rapidly and release purines into the blood. These purines are converted into uric acid, which may strain kidney function. The World Health Organization includes allopurinol among medicines used for conditions involving clinically significant hyperuricemia [2].
The following habits can undermine treatment or increase risk:
Extra caution is needed in these situations:
The HLA-B58:01 genetic variant is associated with a greatly increased risk of severe cutaneous adverse reactions. Testing may be considered before treatment in people from higher-prevalence ancestry groups or those with other risk factors. The Clinical Pharmacogenetics Implementation Consortium advises avoiding allopurinol in carriers of HLA-B58:01 because of this risk [3].
Important interactions include:
Allopurinol is not for you if you have previously had a serious allergic or severe skin reaction to Allopurinol. A previous reaction involving blistering, peeling skin, fever, organ inflammation, or hospitalization is a major warning against re-exposure.
Many people tolerate Allopurinol without major difficulty. Mild effects can include nausea, diarrhea, abdominal discomfort, drowsiness, headache, or altered taste. Taking the tablet after a meal can be useful when stomach upset is the main issue.
Rash needs a different response. A mild-looking skin eruption can be an early warning sign of a severe hypersensitivity reaction, and it should never be ignored. Serious reactions can include fever, facial swelling, mouth sores, blistering, peeling skin, swollen glands, hepatitis, kidney injury, or changes in blood counts.
Allopurinol hypersensitivity syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis are rare but potentially life-threatening. Risk rises with certain genetic backgrounds, reduced kidney function, high starting doses, and some interacting medicines.
Allopurinol is usually the first xanthine oxidase inhibitor selected for long-term gout prevention. Other approaches may be used if urate targets are not reached, if intolerance occurs, or if a different mechanism better fits the person’s medical history.
| Treatment approach | Main mechanism | Practical role |
|---|---|---|
| Allopurinol | Reduces uric acid production by inhibiting xanthine oxidase | Common first-line maintenance option |
| Febuxostat | Also inhibits xanthine oxidase | Alternative for selected patients who cannot use Allopurinol |
| Uricosuric therapy | Increases urinary uric acid elimination | May suit selected patients without high stone risk |
Febuxostat reduces uric acid production through the same broad enzyme target, while uricosuric medicines work through the kidneys. Uricosuric treatment can be less suitable for people prone to uric acid stones because it increases uric acid excretion into urine.
Allopurinol has a long clinical history and is widely used. Its key limitation is the need for careful initiation, dose adjustment in relevant clinical settings, and immediate action if a serious rash appears. The 2020 American College of Rheumatology guideline supports treat-to-target urate management with serial serum urate testing rather than leaving treatment unchanged without monitoring [1].
In clinical practice, physicians focus less on whether a patient has a single quiet month and more on whether serum urate remains controlled over time. The aim is to prevent crystal formation, not merely react to the next painful flare.
A clinician will often explain that gout treatment has two separate jobs: controlling inflammation now and lowering urate for the future. Confusing these roles is one reason people abandon treatment too early. Patients with frequent attacks, tophi, stones, or chronic kidney disease often benefit most from a clear long-term plan with laboratory follow-up.
Allopurinol can be taken at a time that supports consistent daily use. Taking it after food may help if nausea or stomach discomfort occurs. Health Canada’s 2024 product monograph describes oral administration as individualized, with regular use being more relevant than a specific clock time. If more than one daily dose has been prescribed, the prescriber may advise splitting doses. A missed dose should not be doubled unless a clinician gives different instructions.
Some people experience drowsiness, dizziness, or reduced alertness, especially when starting treatment or after a dose change. Avoid driving, climbing, or operating machinery until you know how Allopurinol affects you personally. The EMA’s 2024 medicine-safety framework emphasizes that medicines causing dizziness or somnolence can affect tasks requiring attention. Alcohol can also worsen dizziness and may raise uric acid in some people.
Stop taking Allopurinol and seek urgent assessment for rash, blistering, skin peeling, mouth sores, fever, facial swelling, swollen glands, yellowing of the skin or eyes, dark urine, or unusual bruising. These signs can indicate a severe hypersensitivity reaction affecting the skin or internal organs. The FDA’s 2018 allopurinol prescribing information carries strong warnings about severe skin reactions. Rapid action is far safer than waiting to see whether a rash settles.
Allopurinol can be used in children for specific medical reasons, including certain cancer-treatment settings or rare inherited metabolic conditions. It is not routinely used for ordinary childhood joint pain. Pediatric prescribing requires weight-based clinical assessment, kidney-function review, and specialist direction. WHO’s 2023 paediatric medicine guidance recognizes that children may require different dosing and monitoring approaches from adults.
Yes, rash is one of the best-known adverse effects of Allopurinol, and it ranges from mild eruptions to rare severe skin reactions. A rash should be treated as clinically significant until assessed because it may be the first sign of allopurinol hypersensitivity syndrome. Research published by CPIC in 2013 links HLA-B*58:01 with a much higher risk of severe cutaneous reactions. Do not restart treatment after a rash unless a clinician has clearly assessed the cause.
For chronic gout or recurrent uric acid stones, Allopurinol is often used long term because the tendency to produce excess uric acid can persist. The treatment duration depends on urate levels, flare history, kidney stones, tophi, kidney function, and treatment goals. The American College of Rheumatology’s 2020 guideline supports continuing urate-lowering therapy to maintain target serum urate in people with gout. Long-term use involves periodic review rather than a fixed short course.
Stopping Allopurinol allows uric acid levels to rise again, which can lead to renewed crystal formation and later gout flares. It does not usually require tapering for withdrawal prevention, but treatment changes should be directed by the prescriber because the reason for stopping matters. A serious rash or hypersensitivity symptoms are exceptions where further doses should be avoided immediately pending urgent assessment. The FDA’s 2018 safety information advises individualized management when adverse effects or interacting medicines are present [4].
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took 100 mg of Allopurinol daily for about a year after repeated attacks in my big toe. The first few months were uneven because I still had a flare, but by the end of the year the attacks were much less frequent. Keeping the same morning routine helped.
I took 200 mg of Allopurinol daily for about six months. My uric acid came down over several blood tests, which was reassuring because I could not tell much from day to day. I had mild nausea early on, and taking the tablet after breakfast made that settle.
I took 100 mg of Allopurinol daily for several months, but I stopped for a few days during an ankle flare because I thought the pills caused it. My doctor explained that the flare needed separate treatment and restarted the plan. I wish I had understood that from the beginning.
I took 100 mg of Allopurinol daily for several months after more than one gout attack. I did not feel an instant difference, but after several months I was no longer planning weekends around my foot hurting. The regular bloodwork was the part I initially found annoying.
I took 300 mg of Allopurinol daily for several years with good control until I developed a new itchy rash after another medicine was added. I contacted my clinic quickly and was told not to take another tablet until it was assessed. That caution was the right call.
